Welcome to our dedicated page for Roivant Sciences news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences (ROIVW) delivers innovative biopharmaceutical solutions through its subsidiary-driven model, focusing on unmet needs in immunology and dermatology. This news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including clinical trial results, FDA submissions, and subsidiary partnerships. Our curated feed ensures you never miss critical updates about novel antibody therapies, small molecule advancements, or commercial-stage product launches.
Key resources include earnings reports, research collaborations, and pipeline expansion announcements. Bookmark this page for streamlined tracking of Roivant's progress in autoimmune disease treatments and topical therapeutic innovations. Check regularly for authoritative updates directly impacting market positioning and therapeutic development timelines.
Aruvant Sciences presented clinical data on its gene therapy ARU-1801 for severe sickle cell disease (SCD) at the ASGCT annual meeting on May 16, 2022. The data indicates ARU-1801 significantly reduces vaso-occlusive events and hospitalization days for patients. This therapy uniquely employs reduced intensity conditioning, setting it apart from other treatments. In the ongoing MOMENTUM trial, participants showed durable responses with four out of five experiencing complete resolution of severe events. These findings may enhance patient quality of life and lower healthcare costs.
Roivant Sciences has appointed Dr. Srini Ramanathan as Chief Development Officer, bringing over 20 years of drug development experience from Horizon Therapeutics. Dr. Ramanathan has a proven track record in advancing clinical portfolios and has contributed to multiple drug approvals in virology and oncology. Roivant's subsidiaries, Proteovant Therapeutics and VantAI, have also established collaborations with Blueprint Medicines, Janssen, and Boehringer Ingelheim, focusing on innovative drug development with potential aggregate milestone payments exceeding $1 billion.
Dermavant Sciences announced positive results from the Phase 3 PSOARING 3 long-term extension study for tapinarof cream 1% in treating plaque psoriasis. Over 52 weeks, tapinarof showed durable improvements in efficacy, quality of life, and tolerability without irritation. The study demonstrated significant enhancements in key metrics such as % body surface area (%BSA) affected and Psoriasis Area and Severity Index (PASI). Dermavant aims for FDA approval, with a target action date set for Q2 2022, which could position tapinarof as a novel therapeutic option for psoriasis patients.
Roivant Sciences (Nasdaq: ROIV) announced that CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on March 16, 2022, at 1:15 p.m. ET. A live webcast will be accessible on the Roivant Investor Relations website. Roivant aims to enhance healthcare delivery by addressing inefficiencies and developing transformative medicines through its innovative Roivant platform. For updates, visit www.roivant.com.
Genevant Sciences and Arbutus Biopharma have filed a lawsuit against Moderna for patent infringement related to key patents in nucleic acid delivery technology used in the manufacture of their COVID-19 vaccine, mRNA-1273. The patents involved include U.S. Patent Nos. 8,058,069, 8,492,359, and others. Importantly, Genevant and Arbutus are not seeking to halt the sale or distribution of mRNA-1273. The lawsuit follows a recent legal victory for Genevant and Arbutus, where a court upheld the patentability of their technologies.
Genevant emphasizes the significance of lipid nanoparticle technology in mRNA delivery.
Roivant Sciences has launched Hemavant, a subsidiary that secured a licensing agreement with Eisai Co., Ltd. for RVT-2001, targeting anemia in myelodysplastic syndromes. Dermavant is preparing for the anticipated FDA decision on tapinarof for psoriasis, with favorable Phase 3 trial results in atopic dermatitis. Genevant's patent portfolio was upheld against Moderna, and Immunovant aligned with the FDA for a pivotal trial in myasthenia gravis. As of December 31, 2021, Roivant reported $2.2 billion in cash, with a net loss of $306.1 million for the quarter.
Roivant Sciences (NASDAQ: ROIV) will host a live conference call and webcast on February 14, 2022, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. The call can be accessed at +1-844-224-1923 for domestic and +1-214-989-7105 for international calls. Roivant will also present at three major healthcare conferences this February and March, including the SVB Leerink Global Healthcare Conference and Cowen Healthcare Conference.
Roivant Sciences (Nasdaq: ROIV) announced CEO Matt Gline will present at two conferences: the B. Riley Securities Virtual Oncology Conference on January 27, 2022, at 12:30 p.m. ET, and the SVB Leerink Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. Live webcasts will be available on the Roivant investor website, with archived recordings accessible for 30 days. Roivant aims to enhance healthcare delivery and develop transformative medicines through its innovative platform.
Roivant Sciences (Nasdaq: ROIV) announced a licensing agreement with Eisai Co., Ltd. for global rights to RVT-2001, aimed at treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS). RVT-2001, an orally available small molecule, has been tested in over 80 human subjects. Roivant will expand its clinical trial for RVT-2001 this year. Details will be discussed during a presentation at the J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET.
Roivant began trading on Nasdaq under the ticker ROIV and reported a cash balance of $2.5 billion. Dermavant presented positive results from its Phase 3 PSOARING 3 study of tapinarof for plaque psoriasis, highlighting that 58% of patients achieved a PGA score of 0 or 1 after long-term treatment. Aruvant shared encouraging data from its Phase 1/2 trial of ARU-1801 in sickle cell disease, with zero vaso-occlusive events observed for up to 18 months. Roivant's net loss was $225.6 million for the quarter, significantly up from $53.5 million year-over-year.
